Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy

17.02.2023 - NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on the remestemcel-L development program for the ... Seite 1

Related Keywords

Florida ,United States ,Orlando ,American ,Joanne Kurtzberg ,Duke University Medical Center ,Mesoblast Limited Nasdaq ,Marrow Transplant Research ,Drug Administration ,American Society ,Cellular Therapy ,Immunomodulatory Activity ,Direct Measure ,Product Potency ,Clinical Outcomes ,Steroid Refractory Acute ,Term Survival ,Children Treated ,Jerome Harris ,Distinguished Professor ,Duke University Medical ,